This study evaluates the cost-effectiveness and budget impact to US payers of point-of-care nucleic acid amplification tests (NAAT) for group A streptococcus.
Eliza Kruger, MHEcon
Advertisement
Articles by Eliza Kruger, MHEcon
Advertisement
Latest Updated Articles
- US Cost-effectiveness and Budget Impact of Point-of-Care NAAT for Streptococcus
Published: May 12th 2021 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
2025 Nobel Prize in Medicine Honors Discoveries Behind Regulatory T Cells
2
FDA Expands Roflumilast Use for Atopic Dermatitis to Children Aged 2 to 5 Years
3
Aggressive Therapy Recommendations Following the STRONG-HF Trials: Stephen J. Green, MD
4
Pricing and Insurance Networks in Outpatient Surgery Markets
5
